Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
© Chang et al.; licensee BioMed Central Ltd. 2013
Received: 5 February 2013
Accepted: 11 May 2013
Published: 11 May 2013
Fungal sepsis is an increasingly common problem in intensive care unit patients.Mortality from fungal sepsis remains high despite antimicrobial therapy that is highly active against most fungal pathogens, a finding consistent with defective host immunity that is present in many patients with disseminated fungemia.One recently recognized immunologic defect that occurs in patients with sepsis is T cell "exhaustion" due to increased expression of programmed cell death -1 (PD-1).This study tested the ability of anti-PD-1 and anti-programmed cell death ligand -1 (anti-PD-L1) antagonistic antibodies to improve survival and reverse sepsis-induced immunosuppression in two mouse models of fungal sepsis.
Fungal sepsis was induced in mice using two different models of infection, that is, primary fungal sepsis and secondary fungal sepsis occurring after sub-lethal cecal ligation and puncture (CLP).Anti-PD-1 and anti-PD-L1 were administered 24 to 48 h after fungal infection and effects on survival, interferon gamma production, and MHC II expression were examined.
Anti-PD-1 and anti-PD-L1 antibodies were highly effective at improving survival in primary and secondary fungal sepsis.Both antibodies reversed sepsis-induced suppression of interferon gamma and increased expression of MHC II on antigen presenting cells.Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a second negative co-stimulatory molecule that is up-regulated in sepsis and acts like PD-1 to suppress T cell function, also improved survival in fungal sepsis.
Immuno-adjuvant therapy with anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies reverse sepsis-induced immunosuppression and improve survival in fungal sepsis.The present results are consistent with previous studies showing that blockade of PD-1 and CTLA-4 improves survival in bacterial sepsis.Thus, immuno-adjuvant therapy represents a novel approach to sepsis and may have broad applicability in the disorder.Given the relative safety of anti-PD-1 antibody in cancer clinical trials to date, therapy with anti-PD-1 in patients with life-threatening sepsis who have demonstrable immunosuppression should be strongly considered.
Sepsis, the host response to severe infection, is the 10th leading cause of death in the United States and the mostcommon cause of mortality in most intensive care units [1, 2].Improved treatment protocols have resulted in the majority of patients surviving the initial 72 hours of sepsis onset only to succumb later in the time course of the disease .There is increasing recognition that a state of impaired immunity follows the initial hyper-inflammatory phase of sepsis [4–8].During this phase of impaired immunity, patients are more susceptible to secondary nosocomial infections, often with opportunistic organisms that typically infect immunocompromised individuals.One of the most important opportunistic infections in patients in the ICU is Candida albicans [9–12].Candida infections are currently the third or fourth most common cause of bloodstream infections in many intensive care units.Although excellent antimicrobial therapy against most Candida species exists, mortality remains high at approximately 30 to 40% for fungal sepsis [10–12].
The fact that mortality from fungal infections remains high despite the use of antimicrobial agents that are highly active against fungal organisms, suggests that defects in host immunity may contribute to the persistent high mortality.Therefore, methods that improve host immune function may be fundamental to improving survival. In this regard, recent studies suggest that immuno-adjuvant therapy in invasive fungal infections may be a viable strategy [13–15].IL-7, a pleuripotent cytokine that enhances adaptive immunity throughimmunostimulatory effects on CD4 and CD8 T cells, caused an approximately1.7-fold improvement in survival in a murine fungal sepsis model .In addition to animal studies, a few clinical studies support the use of immuno-adjuvant therapy in invasive fungal infections [14, 15].A randomized trial of interferon gamma (IFN-γ), a potent activator of macrophages and monocytes in HIV patients with cryptococcal meningitis, showed that treatment led to a significantly faster rate of clearing of cerebrospinal fluid, a finding that has been shown to correlate with survival .IFN-γ is currently approved for use in patients with chronic granulomatous disease who have invasive fungal infections .
Another potential strategy for improving host immunologic defenses that has shown efficacy in various infectious models is the use of agents which up-regulateadaptive immunity by blocking inhibitory receptors expressed on T lymphocytes [16–19].T cell activation is carefully controlled by expression of positive and negative co-stimulatory molecules that prevent excessive T cell function.CD28 is the classic positive co-stimulatory receptor that, acting in conjunction with the T cell receptor (TCR), induces T cells to proliferate and produce cytokines including, for example, IL-2 and IFN-γ that have extensive effects on other cells.To prevent excessive T cell activation, lymphocytes express a number of negative co-stimulatory molecules that suppress and down-regulate their function [18, 19].
Programmed cell death-1 (PD-1) is a member of the B7-CD28 superfamily that functions in an inhibitory role.During T cell activation, PD-1 is rapidly induced and expressed on the surface of CD4 and CD8 T cells where it interacts with its ligands PD-L1 and PD-L2 [20–22].PD-L1 is expressed on both hematopoietic and non-hematopoietic cells and its expression is highly up-regulated during inflammatory states .Activation of PD-1 by its ligands causes inhibition ofmanyT cell functions, including proliferation, cytotoxic activity and cytokine production.The essential role of PD-1 in regulating immunity is demonstrated in studies showing that PD-1 knockout mice develop autoimmune diseases, including cardiomyopathy and a lupus-like syndrome [16, 20, 21].Increased T cell expression of PD-1 is known to occur under conditions of chronic antigenic stimulation, such as persistent viral infections, and lead to T cell "exhaustion" [16, 17, 20].These "exhausted" T cells are non-functional, prone to undergo apoptosis, and are unable to participate in an effective immune response, thereby contributing to the chronic nature of the viral infections.Blockade of PD-1using inhibitory antibodies has been shown to restore T cell function, increase antiviral T cell responses, and reduce viral load in certain infections [18, 19].In addition to viral infections, blockade of the PD-1 pathway has improved survival in bacterial infections.Three independent groups demonstrated that blockade of the PD-1 pathway decreased mortality in clinically-relevant animal models of bacterial sepsis [23–25].The potential clinical relevance of these animal studies is highlighted by recent studies showing that PD-1 over-expression on circulating T cells from patients with sepsis correlated with decreased T cell proliferative capacity, increased secondary nosocomial infections and mortality .
The purpose of this study was to determine if inhibition of the T cell negative co-stimulatory PD-1:PD-L1 pathwaycould reverse immune dysfunction and improve survival in primary fungal infections and in secondary fungal sepsis occurring after bacterial infection.Both the anti-PD-1 and the anti-PD-L1 antibodysignificantly improved survival in the two different models of fungal sepsis.This improvement in survival was associated with increased production of IFN-γ, a cytokine which is critical in host defenses against fungal organisms, and reversed the fungal-induced depression of HLA-DR expression in monocytes and dendritic cells.Blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a second negative co-stimulatory molecule that suppresses T cell function, also improved survival in primary and secondary fungal sepsis thereby supporting the concept that immuno-adjuvant therapy offers a rational, new approach to treatment of this highly lethal infection.
Materials and methods
Eight-to-ten-week-old male C57BL6 or CD1 mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) or Charles River Laboratories (Wilmington, MA, USA), respectively.Procedures were approved by the Animal Studies Committee at Washington University School of Medicine.
Flow cytometry antibodies and reagents
The following fluorescently labeled antibodies used for flow cytometrywere purchased from BD Pharmingen (San Diego,CA, USA): BD Pharmingen: CD4-FITC (Cat. # 553729), CD4-PeCy5 (Cat. # 553050), CD8-FITC (Cat. # 553031), B220-PeCy5 (Cat. # 553091), CD11c-FITC (Cat. # 553801), CD274-Pe (Cat. # 558091), CD152-Pe (Cat. # 553720), IFNγ-Pe (Cat. # 554412), I-A/I-E-Pe (Cat. # 557000), CD16/CD32-Block (Cat. # 553142).
The following fluorescently labeled antibodies used for flow cytometry were purchased from eBioscience (San Diego, CA, USA): CD279-Pe (Cat. # 12-9985-82), CD11α-FITC (Cat. # 11-0111-85), MHC classII-Pe (Cat.# 15-5322-82).
Anti-PD-1, anti-PD-L1 and anti-CTLA4 antibodies that were used for in vivo inhibition studies were provided by Bristol-Meyers Squibb (NewYork, NY; USA).The clones for anti-PD-1 and anti-PD-L1 were 4H2 and 14D8, respectively.Two different clones of anti-CTLA-4 were used.Clone G1 and clone G2B were used for single-hit and two-hit models of fungal sepsis, respectively.
Fungal sepsis models
Candida albicans(ATCC MYA-2430)was grown overnight in Difco™Sabouraud dextrose broth medium (Sigma Aldrich, St. Louis, MO;USA).Cells were harvested, washed and suspended in saline to obtain an optical density of either 0.5A600or 0.3A600 for single-hit or two-hit fungal sepsis, respectively,as described .
Two-hit model of cecal ligation and puncture (CLP) followed by Candida albicans
The CLP model was used to induce sub-lethal peritonitis for use in the two-hit model as previously described [13, 27].Mice were anesthetized with isoflurane and a midline abdominal incision was performed.The cecum was ligated and punctured twice with a #27 gauge needle.The abdomen was closed in two layers and mice injected subcutaneously with 1 ml of 0.9% normal saline containing Buprenex(PharmaForce, Columbus, OH; USA)(0.05 mg/kg) subcutaneously and allowed to recover.Imipenem(Merck; Whitehouse Station, NJ; USA)(2.5mg/kg) was given subcutaneously 24h post-CLP.Three days post-CLP, surviving mice received 60 μl of the 0.3A600Candida suspension via tail vein injection.Three days post-CLP was selected as the time point to challenge with Candida because of previous studies which demonstrated that mice had increased susceptibility to Candida (consistent with impaired immunity) at this time point .This dose of Candida caused <10% mortality in naïve mice and, therefore, the much higher mortality in mice that had undergone CLP prior to the Candida challenge highlights the impaired immunity that occurs following CLP.Mice received fluconazole 200 μgintra-peritoneal (i.p.)five days after Candida.Mice were treated with anti-PD-1 (200 μgs), anti-PD-L1 (200 μgs) or anti-CTLA-4 (100 μgs) antibodies beginning at days 2 or 4 post Candida infection.
Primary Candida (single hit) studies
Unanesthetized mice were injected via tail vein with 50 μl of the 0.5A600Candida suspension.Mice were allowed free access to food and water throughout the study.Where specified, the anti-fungal agent fluconazole (200 μg) was administered via i.p. injection.Fluconazole was used in order to show that immunotherapy with anti-PD-1 was effective when added to standard antimicrobial therapy of fungal sepsis.Anti-PD-1 and anti-PD-L1 antibody administration was started two days after the initial Candida infection.Anti-CTLA-4 antibody therapy (50 ugs) was initiated at four days post Candida infection.The percentage of mice survival at Day 12 was recorded.
PD-1 expression in splenic immune cells followingCandida infection
In order to determine the effect of Candida on lymphocyte PD-1 expression following single-hit or two-hit fungal infection, mice were injected with Candida as previously described and spleens were harvested at multiple time points post-Candida infection [13, 27].Splenocytes were prepared and underwent immunostainingwith fluorochrome-conjugated antibodies to CD4 T, CD8 T and PD-1.Flow cytometric analysis (50,000 events/sample) was performed on FACScan (Becton Dickinson, San Jose, CA, USA) and Cell Quest software (BD Pharmigen; San Diego, CA; USA) was utilized to analyze the data .
Quantitation of cytokines
Cytokines were quantified using ELISA Duosets from Invitrogen (Camarillo, CA, USA) and R&D Systems (Minneapolis, MN, USA) employing the μQuantScanning Microplate Spectrophotometer (Bio-Tek Instruments,Winooski, VT, USA) as described [13, 24, 27].
Determination of intracellular IFN-γ production in CD4 and CD8 T cells
At Day 11, spleens were harvested and splenocyte suspensions prepared as previously described .Approximately 10 million splenocytes were plated in sterile wells with 1 ml of complete RPMI 1640 media (Sigma Aldrich, St Louis, MO; USA).Splenocytes were stimulated with anti-CD3 and anti-CD28 and incubated overnight.Approximately 18 h later, a sample of supernatant was obtained and analyzed for secreted cytokines.Next, brefeldin A was added for an additional four hours incubation after which splenocytes were harvested, washed and immunostained for CD4 or CD8.Cells were then fixed,permeabilized and stained for intracellular IFN-γ.The percentage of cells positive for IFN-γ was determined by flow cytometry as previously described .
Data were analyzed with the statistical software Prism (GraphPad, San Diego, CA, USA).Data are reported as the mean ± SEM.For comparison of two groups, the Student's t-test was employed. One-way ANOVA with Tukey's multiple comparison tests was used to analyze data in which there were more than two groups. For survival studies, a log rank test was used.Significance was reported at P <0.05.
Anti-PD-1 and anti-PD-L1 improve survival in two-hit fungal sepsis
Anti-CTLA-4 antibody improves survival in two-hit fungal sepsis
CTLA-4is a negative co-stimulatory molecule that acts in a fashion similar to PD-1 to induce suppression of T cell function .Previous work from our group by Inoue et al.showed thatanti-CTLA-4 antibody improved survival in a peritonitis model of sepsis and in a two-hit model of CLP followed by Candida .The study, examining anti-CTLA-4 in the two-hit fungal sepsis model by Inoue et al., was a small preliminary investigation.To further support the concept that inhibition of negative co-stimulatory molecules represents a viable potential therapeutic approach in fungal sepsis, we examined effects of anti-CTLA-4 antibody in a more thorough manner in both primary and secondary (two-hit) models of fungal sepsis.Anti-CTLA-4 antibody was administered 24 h after Candida infection and survival was recorded.Anti-CTLA-4 caused a significant improvement in survival compared to mice receiving saline diluent(control), that is, 57.9% versus 27.8%, respectively, P < 0.05, (Figure 1B).
Anti-PD-1, anti-PD-L1, and anti-CTLA-4 improve survival in primary (single-hit) fungal sepsis
Lymphocyte PD-1 expression is increased in primary and two-hit fungal sepsis
PD-1 expression was quantitated in the two-hit model of sepsis as well.PD-1 expression was increased on CD4 and CD8 T cells at Day 3 following CLP (prior to Candida infection).CD4 T cell PD-1 expression was also increased at days 9 and 12 following CLP which corresponds to days 6 and 9 following the second-hit Candida infection (Figure 3C).CD8 T cell PD-1 expression was increased at Day 5 post CLP which corresponds to Day 2 following the second-hit Candida infection but not at other times (Figure 3D).
Anti-PD-1, anti-PD-L1 and anti-CTLA-4 increased IFN-γ production in fungal sepsis
Anti-PD-1 and anti-PD-L1 increase MHC II expression on antigen presenting cells
The present results demonstrating that blockade ofPD-1, PD-L1 or CTLA-4 leads to improved survival in both primary and secondary fungal sepsis strongly support the concept that inhibition ofT cell negative co-stimulatory pathways represents an effective therapeutic approach to disseminated fungal sepsis.Previous reports by three independent groups showed that inhibition of the PD-1:PD-L1 pathway improved survival in the clinically relevant CLP model of bacterial sepsis [23–25].Recent studies have also reported that inhibition of PD-1 restores T cell function and decreases viral load in murine models of hepatitis B and HIV-1 [29, 30].In a related fashion, our group has reported that an antagonistic antibody to CTLA-4 improved survival in a clinically-relevant animal model of bacterial peritonitis .Additional studies havedemonstrated that increased CTLA-4 expression adversely affected pathogen clearance in murine models of Helicobacterpylori, Leishmania and Trypanosoma [31–33].Considered together, these studies make a compelling case that modulation of the negative co-stimulatory pathway mediated by PD-1/PD-L1 and CTLA-4 represents a novel and potentially highly effective approach to a broad range of infectious agents.
The findings from the current studies showing that blockade of negative co-stimulatory pathways improves survival in disseminated fungal sepsisprovide additional support for the hypothesis that immunosuppression is a major pathophysiologic phenomenon in sepsis.Although there are multiple interacting mechanisms responsible for immunosuppression in sepsis, including, for example, increased T regulatory cells, increased myeloid derived suppressor cells, and apoptosis-induced depletion of immune effector cells, recent studies highlight the likely role of PD-1 mediated T cell "exhaustion" in impaired immunity [23–25, 34, 35].Guignantet al. showed that PD-1 over-expression occurred on circulating T cells from patients with sepsis and correlated with decreased T cell proliferative capacity, increased secondary nosocomial infections and mortality .Studies from our group documented an increase in the percentage of PD-L1 expressing monocytes in patients who die of sepsis versus sepsis survivors (data not shown).A recent postmortem study from our group also demonstrated significantly increased expression of PD-1 and PD-L1 on splenic T cells and antigen presenting cells respectively in septic versus non-septic patients .This increased expression of PD-1 and PD-L1 was associated with marked suppression of stimulated cytokine production by splenocytes from septic patients; splenocytes from septic patients produced less than approximately 10% of the amount of cytokines produced by splenocytes from critically-ill non-septic patients.Collectively, these studies are consistent with a major role for PD-1:PD-L1-mediated immune suppression in patients with sepsis.
Blockade of PD-1, PD-L1 and CTLA-4 not only offers new hope in infectious disease but also appears especially promising in cancer therapy [21, 22, 36–38].Anti-CTLA-4 antibody reinvigorated the concept of immunotherapy as a valid approach to cancer with its success in inducing significant remissions in patients with widely metastatic malignant melanoma, many of whom had failed other therapies .Anti-PD-1 antibody, which has a better safety profile compared to anti-CTLA-4, produced clinical responses in approximately 25% of patients with a variety of diverse tumors [36, 37].Anti-CTLA-4 and anti-PD-1 restore T cell function thereby reactivating host immunity allowing it to eliminate tumor cells.Remarkably, many remissions with anti-CTLA-4 and anti-PD-1 appear to be durable, that is, they have lasted for over a year, and may be permanent .The encouraging results of cancer immunotherapy with anti-CTLA-4 and anti-PD-1 are highly relevant to sepsis patients because cancer and sepsis share many of the same immunosuppressive mechanisms,including increased T cell CTLA-4 expression and increased PD-1 and PD-L1 expression in T cells and monocytes, respectively, with T cell "exhaustion" [4–8, 34, 35].Sepsis, like cancer, is an ideal condition for persistent antigenic exposure which is thought to be one mechanism driving induction of PD-1/PD-L1 and T cell dysfunction.
Although there are likely a number of mechanisms that are responsible for the protective effect of anti-PD-1, anti-PD-L1 and anti-CTLA-4 in sepsis, one likely mechanism is their ability to reverse the sepsis-induced suppression in IFN-γ production.All three antibodies had demonstrable efficacy in increasing either splenocyte IFN-γ production or the percentage of IFN-γ positive CD4 and/or CD8 T cells (Figures 4, 5, 6, 7).(Note that differing effects on host immunity have recently been observed in animals treated with different isotypeantibodies to CTLA-4 .)T cells are major producers of IFN-γ, which is essential for optimal function of monocytes and macrophages.Sepsis-induced suppression of IFN-γ production is likely a major driving force for the immune suppression in the disorder [41, 42].Administration of IFN-γ during the immunosuppressive phase of sepsis has been reported to be beneficial in several small clinical studies [41, 42].The ability of anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies to improve IFN-γ production may be particularly germane to fungal sepsis.Administration of IFN-γ improves outcome in patients with chronic granulomatous disease who have fungal sepsis.Recently, a trial of IFN-γ in a small number of patients with fungal meningitis showed that IFN-γ leads to more rapid clearing of fungal organisms from the cerebrospinal fluid, an important clinical finding that correlates with survival .
Another interesting finding regarding effects of the anti-PD-1 antibody on cytokines was its action to increase production of the pro-inflammatory cytokine IL-6 and the immunosuppressive cytokine IL-10 (Figure 4).The effect of anti-PD-1 to increase IL-10 in the present study is somewhat surprising given findings by Said et al. who reported that PD-1 induces IL-10 production in monocytes in patients with HIV, thereby resulting in impaired T cell activation .Our findings, showing an effect of anti-PD-1 antibody to increase IL-10 production, are similar to the report by Wong et al. who noted that anti-PD-L-1 antibody caused an increase in both IFN-γ and IL-10 in a lymphocyte incubation study .The increase in IL-10 splenocyte production in the present study was relatively small compared to the larger effect of the anti-PD-1 antibody on IFN-γ production (Figure 4).Thus, we believe that the predominant effect of the anti-PD-1 antibody is to enhance activation of T cells, a highly beneficial effect in sepsis.
Similar to our previous findings in the CLP model of sepsis , the anti-CTLA-4 antibody worsened outcome in fungal sepsis if administered at higher doses or too early during the course of the disease (data not shown).No such adverse effects were observed with anti-PD-1 or anti-PD-L1 antibody at any dose or time of administration (data not shown).Thus, anti-PD-1 and anti-PD-L1 appear to have a better safety profile compared to anti-CTLA-4 antibody and this finding mirrors clinical studies in cancer patients which show a lower incidence of autoimmune effects in patients treated with anti-PD-1 compared to anti-CTLA-4 [36–39].
Additional evidence for beneficial effects of anti-PD-1 and anti-PD-L1 on host immunity is provided by their ability to increase MHC II expression on macrophages and dendritic cells (Figure 8).Decreased MHC II expression is a hallmark of sepsis and is used as a marker of immune suppression during the disorder .MHC II molecules function to present microbial antigens to CD4 T cells thereby activating these cells for optimal response to the infectious challenge.Although both anti-PD-1 and anti-PD-L1 improved dendritic cell and macrophage MHC II expression, anti-PD-L1 had a greater effect than anti-PD-1 (Figure 8).This more robust effect of anti-PD-L1 antibody compared to anti-PD-1 antibody to increase MHC II expression may be related to the fact that PD-L1 is expressed on macrophages and dendritic cells and has direct suppressive effects on these cells.
The present experimental findings providepreclinical hypothesis-generating data which support the contention that immuno-adjuvant therapy with anti-PD-1/PD-L1 and anti-CTLA-4 offers a new approach to treatment of fungal infections and likely infectious disease in general.The remarkable efficacy of anti-PD-1 and anti-CTLA-4 antibody therapy to induce remissions in a relatively high percentage of cancer patients [36–38] is evidence that this immunologic approach has profound effects to enhance host immunity.Sepsis, another life threatening failure of host immunity that shares many immune defects with cancer, is likely amenable to this immuno-stimulatory approach as well.Although serious autoimmune side effects of anti-PD-1 and anti-CTLA-4 have occurred in a small percentage of cancer patients treated with these agents [36–38], these adverse effects would likely be less problematic in patients with sepsis because of two factors.First, compared to cancer patients, most septic patients have more severe impairment in host immunity.Secondly,most patients with sepsis would need only short-term therapy with anti-PD-1 or anti-CTLA-4 and, therefore, would be less likely to develop autoimmunity.Additionally, anti-PD-1 antibody could be tailored to septic patients whose peripheral circulating T cells or monocytes have persistently increased expression of PD-1 or PD-L1, respectively, evidence that the patients have entered an immunosuppressive phase of the disorder.Thus, a readily available biomarker could be used to select ideal candidate patients for immune therapy using these agents.
Blockade of the negative co-stimulatory molecules PD-1, PD-L1 and CTLA-4 improved survival in two models of fungal sepsis.Potential mechanisms of action for the beneficial effects of blocking negative co-stimulatory molecules include increased IFN-γ production and increased expression of MHC II on antigen presenting cells.If ongoing, large phase 3 studies of anti-PD-1 antibody in cancer patientscontinue to show its relative safety, carefully conducted clinical trials of anti-PD-1 antibody should be conducted in patients with sepsis.Such a novel immunologic therapy could represent a major advance against this highly lethal disease.
Fungal sepsis is an increasingly important cause of morbidity and mortality in intensive care unit patients.
Programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), are important inhibitors of immune cell function which have be shown to be increased in patients with sepsis.
Antibodies to PD-1, PD-L1 and CTLA-4 improved survival in two different models of fungal sepsis.
Anti-PD-1 increased production of IFN-γ, an important activator of monocyte/macrophages, and increased expression of major histocompatibility molecule II.
Anti-PD-1 and anti-CTLA-4 antibodies may offer a new immunomodulatory therapeutic approach in fungal sepsis.
cluster of differentiation
cecal ligation and puncture
cytotoxic T-lymphocyte antigen-4
delayed type hypersensitivity response
fluorescent activated cell sorter
human leukocyte antigen-DR
- MHC II:
major histocompatibility complex II
mean fluorescence intensity
programmed cell death 1
programmed cell death ligand 1
T cell receptor
- Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002View ArticlePubMedGoogle Scholar
- Murphy SL: Deaths: final data for 1998. Natl Vital Stat Rep 1998, 48: 1-105.Google Scholar
- Monneret G: How to identify systemic sepsis-induced immunoparalysis. Adv Sepsis 2005, 4: 42-49.Google Scholar
- Adib-Conquy M, Cavaillon JM: Compensatory anti-inflammatory response syndrome. ThrombHaemost 2009, 101: 36-47.Google Scholar
- Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA: The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009, 15: 496-497. 10.1038/nm0509-496PubMed CentralView ArticlePubMedGoogle Scholar
- Ward PA: Immunosuppression in sepsis. JAMA 2011, 306: 2618-2619. 10.1001/jama.2011.1831View ArticlePubMedGoogle Scholar
- Monneret G, Venet F, Pachot A, Lepape A: Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14: 64-78.PubMed CentralView ArticlePubMedGoogle Scholar
- Venet F, Lepape A, Monneret G: Clinical review: flow cytometry perspectives in the ICU - from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care 2011, 15: 231. 10.1186/cc10333PubMed CentralView ArticlePubMedGoogle Scholar
- Lipsett PA: Surgical critical care: fungal infections in surgical patients. Crit Care Med 2006, 34: S215-224. 10.1097/01.CCM.0000231883.93001.E0View ArticlePubMedGoogle Scholar
- Miceli MH, Diaz JA, Lee SA: Emerging opportunistic yeast infections. Lancet Infect Dis 2011, 11: 142-151. 10.1016/S1473-3099(10)70218-8View ArticlePubMedGoogle Scholar
- Arendrup MC: Epidemiology of invasive candidiasis. CurrOpinCrit Care 2010, 16: 445-452.Google Scholar
- Lepak A, Andes D: Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit Care Clin 2011, 27: 123-147. 10.1016/j.ccc.2010.11.001View ArticlePubMedGoogle Scholar
- Unsinger J, Burnham CA, McDonough J, Morre M, Prakash PS, Caldwell CC, Dunne WM Jr, Hotchkiss RS: Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 2012, 206: 606-616. 10.1093/infdis/jis383PubMed CentralView ArticlePubMedGoogle Scholar
- Jarvis JN, Rebe K, Williams GN, Bicanic T, Williams A, Schutz C, Bekker LG, Wood R, Harrison TS: Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012, 26: 1105-1113. 10.1097/QAD.0b013e3283536a93PubMed CentralView ArticlePubMedGoogle Scholar
- Armstrong-James D, Harrison TS: Immunotherapy for fungal infections. CurrOpinMicrobiol 2012, 15: 434-439.Google Scholar
- Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ: The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007, 8: 239-245. 10.1038/ni1443View ArticlePubMedGoogle Scholar
- Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26: 677-704. 10.1146/annurev.immunol.26.021607.090331View ArticlePubMedGoogle Scholar
- Brown KE, Freeman GJ, Wherry EJ, Sharpe AH: Role of PD-1 in regulating acute infections. CurrOpinImmunol 2010, 22: 397-401.Google Scholar
- Jin HT, Ahmed R, Okazaki T: Role of PD-1 in regulating T-cell immunity. Curr Top MicrobiolImmunol 2011, 350: 17-37.Google Scholar
- Martinic MM, von Herrath MG: Novel strategies to eliminate persistent viral infections. Trends Immunol 2008, 29: 116-124. 10.1016/j.it.2007.12.002View ArticlePubMedGoogle Scholar
- Saresella M, Rainone V, Al-Daghri NM, Clerici M, Trabattoni D: The PD-1/PD-L1 pathway in human pathology. CurrMol Med 2012, 12: 259-267.Google Scholar
- Chen DS, Irving BA, Hodi FS: Molecular pathways: next-generation immunotherapy - inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012, 18: 6580-6587. 10.1158/1078-0432.CCR-12-1362View ArticlePubMedGoogle Scholar
- Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, Ayala A: PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. ProcNatlAcadSci USA 2009, 106: 6303-6308. 10.1073/pnas.0809422106View ArticleGoogle Scholar
- Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS: Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J LeukocBiol 2010, 88: 233-240.View ArticleGoogle Scholar
- Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z: PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010, 14: R220. 10.1186/cc9354PubMed CentralView ArticlePubMedGoogle Scholar
- Guignant C, Lepape A, Huang X, Kherouf H, Poitevin F, Malcus C, Cheron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F: Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011, 15: R99. 10.1186/cc10112PubMed CentralView ArticlePubMedGoogle Scholar
- Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, Hotchkiss RS: Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 2010, 78: 1582-1592. 10.1128/IAI.01213-09PubMed CentralView ArticlePubMedGoogle Scholar
- Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS: Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 2011, 36: 38-44. 10.1097/SHK.0b013e3182168ccePubMed CentralView ArticlePubMedGoogle Scholar
- Tzeng HT, Tsai HF, Liao HJ, Lin YJ, Chen L, Chen PJ, Hsu PN: PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 2012, 7: e39179. 10.1371/journal.pone.0039179PubMed CentralView ArticlePubMedGoogle Scholar
- Palmer BE, Neff CP, Lecureux J, Ehler A, Dsouza M, Remling-Mulder L, Korman AJ, Fontenot AP, Akkina R: In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol 2012, 190: 211-219.PubMed CentralView ArticlePubMedGoogle Scholar
- Anderson KM, Czinn SJ, Redline RW, Blanchard TG: Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection. J Immunol 2006, 176: 5306-5313.View ArticlePubMedGoogle Scholar
- Johanns TM, Ertelt JM, Rowe JH, Way SS: Regulatory T cell suppressive potency dictates the balance between bacterial proliferation and clearance during persistent Salmonella infection. PLoSPathog 2010, 6: e1001043.Google Scholar
- Martins GA, Tadokoro CE, Silva RB, Silva JS, Rizzo LV: CTLA-4 blockage increases resistance to infection with the intracellular protozoan Trypanosomacruzi . J Immunol 2004, 172: 4893-4901.View ArticlePubMedGoogle Scholar
- Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306: 2594-2605. 10.1001/jama.2011.1829PubMed CentralView ArticlePubMedGoogle Scholar
- Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O'Malley KA, Wynn JL, Antonenko S, Al-Quran SZ, Swan R, Chung CS, Atkinson MA, Ramphal R, Gabrilovich DI, Reeves WH, Ayala A, Phillips J, Laface D, Heyworth PG, Clare-Salzler M, Moldawer LL: MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007, 204: 1463-1474. 10.1084/jem.20062602PubMed CentralView ArticlePubMedGoogle Scholar
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Pardoll DM, Anders RA, Korman AJ, Agrawal S, Gupta A, Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366: 2443-2454. 10.1056/NEJMoa1200690PubMed CentralView ArticlePubMedGoogle Scholar
- Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Drake CG, Camacho LH, Kauh J, Odunsi K, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366: 2455-2465. 10.1056/NEJMoa1200694PubMed CentralView ArticlePubMedGoogle Scholar
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363: 711-723. 10.1056/NEJMoa1003466PubMed CentralView ArticlePubMedGoogle Scholar
- Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL: Durable cancer regression off-treatment and effective re-induction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013, 19: 462-8. 10.1158/1078-0432.CCR-12-2625PubMed CentralView ArticlePubMedGoogle Scholar
- Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ: Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013, in press.Google Scholar
- Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997, 3: 678-681. 10.1038/nm0697-678View ArticlePubMedGoogle Scholar
- Nalos M, Santner-Nanan B, Parnell G, Tang B, McLean AS, Nanan R: Immune effects of interferon gamma in persistent staphylococcal sepsis. Am J RespirCrit Care Med 2012, 185: 110-112. 10.1164/ajrccm.185.1.110View ArticleGoogle Scholar
- Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP: Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. NatMed 2010, 16: 452-9.Google Scholar
- Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, Weber JS: Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen specific CTLS. IntImmunol 2007, 19: 1223-1234.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.